Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications

Antibody Therapeutics
Yong ZhuMitchell Ho

Abstract

Although there are only two bispecific antibody (bsAb) drugs in the market, around 100 bsAb drug candidates are in clinical development. BsAbs have gained fast growing investment and attractions from the biopharmaceutical industry and academia in recent years. Antibody Engineering & Therapeutics 2019 (AET 2019) was held in San Diego, USA, from December 9th to 13th, 2019. This year's AET certainly reflected the trend. In this report, we selected eleven presentations from AET 2019 to highlight bsAbs' design and their potentials in cancer therapy. These presentations have discussed emerging strategies to improve bispecific antibody drugs in efficacy, safety, and production. As compared to CAR-Ts, some T cell-redirecting bsAbs may potentially achieve comparable efficacies with less side effects and toxicities, as evidenced with both preclinical and clinical data reviewed at the conference. Several approaches to reduce T cell engagers' toxicities including conditionally active bsAbs and IgM-based bsAbs were also presented and discussed at the conference. For the first time, The Antibody Society and the Chinese Antibody Society jointly held a special session at the AET.

References

Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Roland E Kontermann
Jun 22, 2011·Proceedings of the National Academy of Sciences of the United States of America·Wolfgang SchaeferChristian Klein
Nov 14, 2014·Science Translational Medicine·Antonio DiGiandomenicoC Kendall Stover
Feb 1, 2015·Molecular Immunology·Christoph SpiessPaul J Carter
Nov 4, 2016·EMBO Molecular Medicine·Jörg T RegulaGuido Hartmann
Oct 6, 2017·Protein Engineering, Design & Selection : PEDS·Maximilian BönischFlorian Rüker
Jun 27, 2019·MAbs·Stephanie KapelskiMark L Chiu
Jan 16, 2020·Immunity·Priti S Hegde, Daniel S Chen

❮ Previous
Next ❯

Citations

Oct 31, 2020·Frontiers in Immunology·Bingyi YangQianjin Lu

❮ Previous
Next ❯

Software Mentioned

WuXiBody
CrossMab
Affimed

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Related Papers

Sheng wu gong cheng xue bao = Chinese journal of biotechnology
Jintong YeXiaodong Zhu
Drug Design, Development and Therapy
Sergey E SedykhGeorgy A Nevinsky
© 2021 Meta ULC. All rights reserved